The present relates to Antibodies and Antigen binding portions thereof that specifically bind to CD40, with Preference, Human CD40, CD40 and functioning as agonists. This is also related to Human anti-cd40 Antibodies and Antigen binding portions thereof.This also relates to Antibodies that are Chimeric, biespec\u00edficos derived single Chain Antibodies or portions of fusion proteins. This also relates to heavy and light chain immunoglobulins isolated from Human anti-cd40 Antibodies and Nucleic Acid molecules which encode such immunoglobulins.This also relates to methods for producing Human anti-cd40 Antibodies, compositions comprising these Antibodies and Methods of using the Antibodies and compositions for diagnosis and treatment.This also provides Methods of gene therapy through the use of nucleic acid molecules that Encode the Molecules of immunoglobulin heavy and \/ or lighter comprising Human anti-cd40 Antibodies. This also relates to transgenic animals comprising Nucleic Acid Molecules of the present.Claim 1: a human or Chimeric monoclonal antibody or Antigen binding portion thereof, which binds specifically to human CD40 and active, in which the Antibody or Antigen of the same link portion comprises: a) a heavy chain comprising sequences d And a heavy chain amino acids of CDR1, CDR2 and CDR3 heavy chain a heavy chain,A variable region of heavy chain, where the amino acid sequence of the heavy chain of the CDR1 and CDR2 heavy chain is selected independently from a CDR1 and CDR2 a variable region of heavy chain, respectively.Where the sequence of the variable region of heavy chain comprises not more than 18 amino acid changes of the Amino Acid Sequence encoded by a Gene germline VH + 4 - 3 - 30, 59, 1 - 2, 3 - 0 or 30.3. Where the amino acid sequence of the heavy chain CDr3 is a CDr3 region of a heavy chain variable, where the variable region of heavy chain is selected from the group consisting of: i) a variable region of heavy chain Antibody selected entr And
